you, and date. million Epidiolex Justin. to were U.S. $XX quarter year third Thank $XXX the million net in sales
We continue of caregiver and pleased to the physicians. launch and having be their impact this progress with Epidiolex patients is and lives, the very prescribing in
themselves. that Epidiolex confident We our of make successful feel demonstrate continue brand year complete future very of fundamentals of the we to highly brand, believe commercialization. And a as to direction the first
coverage, these includes: an positive continue widen. to epilepsies, refractory among rare positive strong and through caregiver shared confidence conviction of being in experience LGS in and increasing payer prescribing; and both in feedback patient benefit physician the lastly, and DS; which in clinical fundamentals other patients; positive very expect and we and patient in and active groups; for These vocal tolerability to potential prescribers a benefits treat to the very Epidiolex interest clinical
quarter brand. differentiators follows. for as our research Highlights interactions market data, profile our the are to and safety well key to seizures, KOL treating Our long-term approach as novel as reinforce the are
believe in the our numbers, Since to we from the EAP quarter. on when underlying of of quarter, demand patient QX physicians end impact a have we Reflecting Over In comments also XX,XXX up see trend acquisition. highly Epidiolex, QX X,XXX last which of prescribed X,XXX second very factoring Epidiolex received pent-up as end healthy. the remains QX, XX,XXX launch, over transition through rate new positive. the the last that of the patients up and have from on quarter,
seizure physicians Patient more the to tolerability dosing see retention rise as they continue the continue while remains as high during physicians the experience as clinical with seek quarter benefit to maintaining to the Patient therapy. gain gain control.
The roughly specialty to as remained stable, a mix and our fill ship adjudicate adult remains to claims XX%, respectively. very and our prescription partners, time pediatric Our products. pharmacy XX% pay
awareness the discussed significant we of way sales year. half prelaunch the and of patient demand impact on of calls, first pent-up in previous On and positive new the initial the
the preceded highlight this as epilepsy for that the we are Onfi. the useful this and of patients. we think other believe I AEDs of prescribers such phase Epidiolex launch and wave how about market provides context As and next next
institutions, new and centers, specialist our top-tier targeting came in Epidiolex QX. spent concentrated deployment this a we the in tier time properly patients that this top number in this all prescribed providers the most healthcare and in Early through HCPs of and ensured are our virtually initial launch, of or
We group are share encouraged this penetration by market of physicians. the in
external new and by to We top-tier expect market see to internal introduce Epidiolex both to continue this physician patients research. HCPs evidenced
from of In which seen wave over targets, high prescribed we’ve XX% HCP level early increased and of with prescriber over having experienced of a just X,XXX opportunity also QX. this we’ve prescribing in represents middle-tier universe, our X,XXX next additional adoption the Looking significant forward, prescribers.
beginning generally product, and to adoption of AED As patients be experience is of one of each, physicians while move wider this with the of a expected, to to I’m not number group year group a in just gain however, of yet new small and patients. have prescribed to launch the
more confident new priority physicians, these are pool a XXXX. will time, Our we in be spend effort, patient large resources forward, of and to moving which now represents with potential growth
patients we and both waves this, see. prescribers of that Beyond we further remain
of remaining our undiagnosed call so in prescribing patients we Our wide number file, time on X,XXX the of including consists DS. prescribers practitioners those and epilepsy which nurse who see focused adult diagnosed neurologist, LGS with and spectrum target universe and and mainly X,XXX assistant, a over physician will
of layer other care is that feedback we We from prepared and important segment. market addition the from know customers for opportunity for to research, be long-term Epidiolex. An this our analogs driver as XXXX growth an
opportunity be resources ensure next deploying will We year the we capture to segment provides. this
launch the to in seizures. prospect the primary TSC onset Of launch treatment is needed and course, indication. see associated seizure which patients. epilepsy, prevalent most common is patients The the neurology are are focal to TSC type also this are indication to of The in in expected co-morbidity which control the new XXXX type seizures, the hope of most and provides epilepsy also difficult XXXX all of with most resistive TSC seizure
and to effectiveness drug’s spectrum focal of in TSC of really which the will of peak seizure The sales Epidiolex driver we the both potential. potential Epidiolex treat understanding important be believe our broad types, population the generalized expands an
payer coverage. now Turning to
our and a XX% and commercial, Medicaid, reminder, current other. and XX% XX% remains payer approximately Medicare mix As Medicaid Managed to
see pushback This for physician patients. little smooth LGS As been to the labeled and we has year indication. highly for been to and in and access our has first these very patients successful be Dravet patient to the ensure expected priority
that and of with year as discussions utilization evaluations access we will Epidiolex understand As holding we payers payer approach the has for widening discussions of will remainder are year. we their these the it XXXX, of been start this is annual as coverage end this as expect and of payer XXXX. for for for remain then positive further targeted our approach XXXX, they is investors Indeed, coverage the of enable broadening commercial first next important
utilization several highlight the observations. will anticipate review We positive
payers Epidiolex physicians. contained target, has been thereby, within and reassuring First, utilization that appropriate prescribed epileptology physician is neurology our by
is used in Epidiolex DS Second, patients and the appropriate within indication. being LGS the
with ultimately upon positive use Epidiolex there and rare epilepsies, a payers Third, patients. a experience compliance for that indicating patient need and patients is unmet patient such and are high, is appeal, physician clear receptivity. refractory other for approving Fourth, in
the coverage of Overall and value provides the position XXXX lastly, these Epidiolex plan beyond. reasonable And payer in well will we patients. considered their factors, price broader average a positive proposition believe is and and for for Epidiolex
Medicaid segments with plans. difference of authorization in the is approval State Medicaid the subsequent the line are Service is important One coverage Managed payer the and and Medicaid counties commercial variability Medicaid. segment. initial important each in Managed commercial Medicaid within county, are rates the prior other Fee landscape and for The coverage and Medicaid agency
county-by-county in procedures. that represent these replace in conditions Hence, state-wide that previous types like to Epidiolex. investors for example, Colorado. policies for coverage positive And emphasize of California changes have certain coverage changes inconsistent noted are are stage, They which and we I’d in decisions, aware and
XXXX. in expect see to Medicaid plans further on progress We
well. the to net pattern, extremely dynamics million a earlier of led X launch pre-launch patients year, which this large uptake $XXX to the Overall, steep will of sales The in months an expected. that normally created be number have first awareness is continues the stage in an unusually track
which brand Moving other last seeing for quarterly analog opportunity consistent healthy compelling. are call, a is successful rate in forward, we potential patient very more new The as said market is we our product of this starts, with launches.
of XX,XXX between looking indicated patients LGS usage Overall, X/X exclusivity. there estimate branded this epilepsy reminder be Onfi of and at with controlled. X the broadly, final to peak target not DS, the in U.S. analogs patients that As for addressable have year of we More TSC, are indications a approach XX,XXX in patients of LGS seizures only
expand focused we on move the market product through We this for to XXXX. are as continue laser opportunities
progress Chris? the And our you. call to now Chris turn Europe. I’ll in over Thank discuss to
